Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Vaccine

• Publication date

  2010-11-10

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1016/j.vaccine.2010.09.049PMID 20883739
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cost-effectiveness in health and medicine

  2016cited by this paper
• Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.

  2010cited by this paper
• Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.

  2010cited by this paper
• Effect of pneumococcal conjugate vaccine on pneumococcal meningitis.

  2009cited by this paper
• Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination.

  2009cited by this paper
• Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines.

  2009cited by this paper
• OR Practice - Catch-Up Scheduling for Childhood Vaccination

  2009cited by this paper
• Parapneumonic Empyema Deaths during Past Century, Utah

  2009cited by this paper
• Deaths: final data for 2006.

  2009cited by this paper
• Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States.

  2009cited by this paper
• An economic analysis of the universal varicella vaccination program in the United States.

  2008cited by this paper
• Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States.

  2008cited by this paper
• Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects

  2008cited by this paper
• Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults.

  2008cited by this paper
• Trends in Acute Otitis Media-Related Health Care Utilization by Privately Insured Young Children in the United States, 1997–2004

  2008cited by this paper
• Influenza and S. pneumoniae Vaccination: Two Examples of Indirect Benefits of Child and Infant Vaccination

  2008cited by this paper
• Progress in introduction of pneumococcal conjugate vaccine--worldwide, 2000-2008.

  2008cited by this paper
• Surveillance for Invasive Pneumococcal Disease During 2000–2005 in a Population of Children Who Received 7-Valent Pneumococcal Conjugate Vaccine

  2007cited by this paper
• Cost-Effectiveness of Routine Childhood Vaccination for Hepatitis A in the United States

  2007cited by this paper
• Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis.

  2007cited by this paper
• Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States.

  2007cited by this paper
• Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.

  2007cited by this paper
• United States life tables, 2004.

  2007cited by this paper
• Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine.

  2007cited by this paper
• Impact of the Pneumococcal Conjugate Vaccine on Pneumococcal Parapneumonic Empyema

  2006cited by this paper
• National Impact of Universal Childhood Immunization With Pneumococcal Conjugate Vaccine on Outpatient Medical Care Visits in the United States

  2006cited by this paper
• Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.

  2006cited by this paper
• Cost-Effectiveness of Pneumococcal Conjugate Vaccine: Evidence From the First 5 Years of Use in the United States Incorporating Herd Effects

  2006cited by this paper
• Health Benefits, Risks, and Cost-Effectiveness of Influenza Vaccination of Children

  2006cited by this paper
• Effectiveness of Heptavalent Pneumococcal Conjugate Vaccine in Children Younger Than 5 Years of Age for Prevention of Pneumonia: Updated Analysis Using World Health Organization Standardized Interpretation of Chest Radiographs

  2006cited by this paper
• Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.

  2005cited by this paper
• Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine.

  2004cited by this paper
• Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.

  2004cited by this paper
• Cost-Effectiveness of Conjugate Meningococcal Vaccination Strategies in the United States

  2004cited by this paper
• The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine.

  2003cited by this paper
• The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison.

  2002cited by this paper
• Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

  2002cited by this paper
• Guidelines for the management of community-acquired pneumonia. Current recommendations and antibiotic selection issues.

  2001cited by this paper
• Economic burden of pneumonia in an employed population.

  2001cited by this paper
• Guidelines for the management of community-acquired pneumonia. Current recommendations and antibiotic selection issues.

  2001cited by this paper
• Complications of meningococcal disease in college students.

  2001cited by this paper
• Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children.

  2000cited by this paper
• Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).

  2000cited by this paper
• Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children

  2000cited by this paper
• Preventing pneumococcal disease among infants and young children : recommendations of the Advisory Committee on Immunization Practices (ACIP)

  2000cited by this paper
• Bureau of Labor Statistics Web Site

  2000cited by this paper
• Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).

  1997cited by this paper

• Delta price cost-effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in Switzerland.

  2026cites this paper
• A comparative analysis of pediatric pneumococcal vaccination strategies: a dynamic model of PCV20 vs. PCV15 and PCV13.

  2026cites this paper
• Global Assessment of Health Utilities Associated with Pneumococcal Disease in Children—Targeted Literature Reviews

  2025influential citation
• Economic evaluation of PCV21 in PCV-naïve adults aged 50-64 years in the United States.

  2025cites this paper
• Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease in the Greek pediatric population

  2025cites this paper
• Economic evaluation of PCV21 in vaccine-naïve adults aged 19–64 years with underlying medical conditions in the United States

  2025cites this paper
• Cost-effectiveness analysis of routine pediatric vaccination of 15-valent pneumococcal conjugate vaccine in South Korea

  2025cites this paper
• Health and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) for adults in Japan: a delta price approach

  2024cites this paper
• Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants.

  2024cites this paper
• Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13

  2024influential citation
• Lifetime Health and Economic Burden of Invasive Pneumococcal Diseases Attributable to V116 Serotypes Among Adults in the United States

  2024cites this paper
• Cost-Effectiveness Analysis of Routine Childhood Immunization with 20-Valent versus 15-Valent Pneumococcal Conjugate Vaccines in Germany

  2024cites this paper
• Cost-Effectiveness Analysis of the Use of V116, a 21-Valent Pneumococcal Conjugate Vaccine, in Vaccine-Naïve Adults Aged ≥ 65 Years in the United States

  2024cites this paper
• Burden of invasive pneumococcal disease, non-invasive all-cause pneumonia, and acute otitis media in hospitalized US children: a retrospective multi-center study from 2015 to 2020

  2024cites this paper
• Cost-Effectiveness Analysis of Routine Use of 15-Valent Pneumococcal Conjugate Vaccine in the US Pediatric Population

  2023influential citation
• Appropriateness of strategy comparisons in cost-effectiveness analyses of infant pneumococcal vaccination: a systematic review

  2023cites this paper
• Cost-effectiveness analysis of pediatric immunization program with 15-valent pneumococcal conjugate vaccine in Japan

  2023influential citation
• Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population

  2023cites this paper
• Value of the Immunization Program for Children in the 2017 US Birth Cohort.

  2022cites this paper
• Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong

  2022cites this paper
• What Contributes to COVID-19 Vaccine Hesitancy? A Systematic Review of the Psychological Factors Associated with COVID-19 Vaccine Hesitancy

  2022cites this paper
• Cost-effectiveness analysis of domestic 13-valent pneumococcal conjugate vaccine for children under 5 years of age in mainland China

  2021cites this paper
• Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries

  2021cites this paper
• A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK

  2021cites this paper
• Comparing Watchful Waiting Approach vs. Antibiotic Therapy in Children with Nonsevere Acute Otitis Media: A Randomized Clinical Trial

  2021cites this paper
• Vaccine market and production capabilities in the Americas

  2021cites this paper
• Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts

  2020cites this paper
• Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations

  2020cites this paper
• Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States

  2020cites this paper
• Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany

  2018cites this paper
• Nasopharyngeal colonisation and antimicrobial resistance of Streptococcus pneumoniae in Hong Kong children younger than 2 years.

  2018cites this paper
• Impact of 13valent vaccine for prevention of pneumococcal diseases in children and adults at risk: possible sceneries in Campania region.

  2018cites this paper
• Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine

  2018cites this paper
• Determinants of the receipt of the 9-valent human papillomavirus vaccine in the first year after introduction in North Carolina.

  2018cites this paper
• Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumococcal carriage in Fiji: results from four annual cross-sectional carriage surveys

  2018cites this paper
• Impact of introduction of the 9-valent human papillomavirus vaccine on vaccination coverage of youth in North Carolina.

  2018cites this paper
• Inclusion of the value of herd immunity in economic evaluations of vaccines. A systematic review of methods used.

  2017cites this paper
• The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: A systematic review and meta-analysis.

  2017cites this paper
• Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis

  2017cites this paper
• Conjugate and 23-valent pneumococcal polysaccharide booster vaccination in asplenic patients with thalassemia major: A randomized clinical trial study

  2017cites this paper
• Immunization, Antibiotic Use, and Pneumococcal Colonization Over a 15-Year Period

  2017cites this paper
• Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

  2016cites this paper
• Antimicrobial Stewardship (AMS) in the Community

  2016influential citation
• Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion.

  2015cites this paper
• PCV13 in the USA: early successes and potential challenges.

  2015cites this paper
• Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: a review of economic evaluations (2006-2014).

  2015cites this paper
• The economic burden of childhood invasive pneumococcal diseases and pneumonia in Taiwan: Implications for a pneumococcal vaccination program

  2015cites this paper
• Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia

  2015cites this paper
• Management of Community-Acquired Pneumonia in Hospitalized

  2015cites this paper
• A current and historical perspective on disparities in US childhood pneumococcal conjugate vaccine adherence and in rates of invasive pneumococcal disease: Considerations for the routinely-recommended, pediatric PCV dosing schedule in the United States

  2015cites this paper
• Association Between Pediatric Vaccination Rates And Patterns Of Pneumococcal Disease In Adults In The Pcv7 And Pcv13 Eras

  2015influential citation
• Management of Community-Acquired Pneumonia in Hospitalized Children

  2015cites this paper
• Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia

  2014cites this paper
• Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies

  2014cites this paper
• Role of pneumococcal vaccination in prevention of pneumococcal disease among adults in Singapore

  2014cites this paper
• Do we know the real benefi ts of PCV13

  2014cites this paper
• Estimated public health impact of nationwide vaccination of infants with 7-valent pneumococcal conjugate vaccine (PCV7) in China.

  2014cites this paper
• Herd protection induced by pneumococcal conjugate vaccine.

  2014cites this paper
• Bacterial meningitis after radiofrequency diathermy for adenoid hypertrophy

  2014cites this paper
• Do we know the real benefits of PCV13?

  2014cites this paper
• Phenotypic and genotypic analysis of Streptococcus pneumoniae diversity during the introduction of pneumococcal conjugate vaccines in the UK

  2014cites this paper
• Impact of 13-Valent Pneumococcal Conjugate Vaccination on Streptococcus pneumoniae Carriage in Young Children in Massachusetts.

  2014cites this paper
• 13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Infants, Children, and Adolescents

  2013cites this paper
• Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States

  2013influential citation
• Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.

  2013cites this paper
• Cost-Effectiveness of Using 2 vs 3 Primary Doses of 13-Valent Pneumococcal Conjugate Vaccine

  2013cites this paper
• Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule.

  2013cites this paper
• The Health Economic Impact of Universal Infant Vaccination with the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine as Compared with 13-Valent Pneumococcal Conjugate Vaccine in Hong Kong.

  2013cites this paper
• Increased nasopharyngeal carriage of serotypes 6A, 6C, and 6D Streptococcus pneumoniae after introduction of childhood pneumococcal vaccination in Hong Kong.

  2013cites this paper
• Reply to: economic evaluation of second generation pneumococcal conjugate vaccines in Norway.

  2013cites this paper
• Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults.

  2013cites this paper
• Epidemiologic and Clinical Implications of Second-Generation Pneumococcal Conjugate Vaccines

  2013cites this paper
• Immunization update IV.

  2013cites this paper
• Systematic review of incremental non-vaccine cost estimates used in cost-effectiveness analysis on the introduction of rotavirus and pneumococcal vaccines.

  2013cites this paper
• Epidemiologic and Clinical Implications of Second-Generation Pneumococcal

  2013cites this paper
• Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise

  2012cites this paper
• Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada

  2012cites this paper
• 7-Valent pneumococcal conjugate vaccine and otitis media: effectiveness of a 2-dose versus 3-dose primary series.

  2012cites this paper
• Pediatric Invasive Pneumococcal Disease in the United States in the Era of Pneumococcal Conjugate Vaccines

  2012cites this paper
• Linking data and models: the importance of statistical analyses to inform models for the transmission dynamics of infections.

  2012cites this paper
• Economic evaluation of vaccination programme of 7-valent pneumococcal conjugate vaccine to the birth cohort in Japan.

  2012cites this paper
• Pneumonia immunization in older adults: review of vaccine effectiveness and strategies

  2012cites this paper
• Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland.

  2012cites this paper
• Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011.

  2012cites this paper
• The 13-Valent Pneumococcal Conjugate Vaccine for Invasive Pneumococcal Disease in Alaska Native Children: Results of a Clinical Trial

  2012cites this paper
• Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults

  2012cites this paper
• Cost–effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions

  2012cites this paper
• Economic evaluation of vaccination programme of 13-valent pneumococcal conjugate vaccine to the birth cohort in Japan.

  2012cites this paper
• Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data

  2012influential citation
• Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.

  2012cites this paper
• Viral–Bacterial Interactions in Acute Otitis Media

  2012cites this paper
• Use of the 13-valent pneumococcal conjugate vaccine in infants and young children

  2012cites this paper
• Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years.

  2012cites this paper
• Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children.

  2011influential citation
• Antibiotic Resistance and Treatment Update of Community-Acquired Pneumonia

  2011cites this paper
• Insights into the epidemiology of drug-resistant Streptococcus pneumoniae and closely-related streptococci in the era of conjugate vaccines

  2011cites this paper
• Review on the immunogenicity and safety of PCV-13 in infants and toddlers

  2011cites this paper
• Antibiotic Resistance and Treatment Update of Community-Acquired Pneumonia

  2011influential citation
• Modeling the decline in pneumococcal acute otitis media following the introduction of pneumococcal conjugate vaccines in the US.

  2011cites this paper
• Konjuge Pnömokok Aşılarında Son Gelişmeler: 13-Valanlı Konjuge Pnömokok Aşısı Recent Advances in Pneumococcal Conjugate Vaccines: A 13-Valent Pneumococcal Conjugate Vaccine

  2011cites this paper